Results 121 to 130 of about 40,633 (287)
Aims The study aims to systematically assess the diagnostic performance of cardiac magnetic resonance (CMR) and nuclear scintigraphy (index tests) for the diagnosis and differentiation of subtypes of cardiac amyloidosis.
Jack Brownrigg+3 more
doaj +1 more source
Cardiovascular Magnetic Resonance in Cardiac Amyloidosis [PDF]
Background: Systemic amyloidoses are an underdiagnosed, but increasingly recognized group of progressive disorders characterised by the extracellular deposition of misfolded proteins in one or more organs.
Martinez de Azcona Naharro, Ana
core
Skeletal muscle and subcutaneous fat quantity as prognostic indicators in cardiac amyloidosis
Aims Disease‐related changes in body composition are associated with worse outcomes in chronic heart failure. In cardiac amyloidosis (CA), the prognostic value of direct body composition measures is understudied. Methods and results We identified 160 consecutive patients with CA (transthyretin [ATTR] or light chain [AL]) diagnosed between 2001 and 2021
Joshua Longinow+4 more
wiley +1 more source
Introduction Cardiac amyloidosis is a rarely reported and potentially fatal variant of the systemic disease. Its early diagnosis could potentially lead to significantly improved clinical outcomes.
Nahid Senobari+7 more
doaj +1 more source
Cardiac Amyloidosis Involving the Conduction System and the Aortocoronary Neuroreceptors [PDF]
Alberto Volpi+4 more
openalex +1 more source
Heart failure (HF) with supranormal ejection fraction (HFsnEF) is an unnoticed but emerging entity in HF. This study showed that HFsnEF carries a similarly increased cardiovascular risk as HF with reduced ejection fraction (HFrEF) and distinct structural and proteomic characteristics from HFrEF, warranting a further comprehensive understanding and ...
Yasuhiko Sakata+19 more
wiley +1 more source
Sudden death in a patient with amyloidosis of the cardiac conduction system. [PDF]
Derek C. Allen, Cathal Doherty
openalex +1 more source
Long‐term efficacy of tafamidis in patients with ATTR‐CM in ATTR‐ACT and its LTE by NAC stage at ATTR‐ACT baseline. ATTR‐ACT, Tafamidis in Transthyretin Cardiomyopathy Clinical Trial; ATTR‐CM, transthyretin amyloid cardiomyopathy; NAC, National Amyloidosis Centre.
Thibaud Damy+4 more
wiley +1 more source
Left Ventricular Systolic Dysfunction Precipitated by Verapamil in Cardiac Amyloidosis [PDF]
Arthur Pollak, Rodney H. Falk
openalex +1 more source